Gallbladder Cancer

Achieving negative margins through aggressive extended radical surgery may be a feasible treatment option in carefully selected patients; however, the oncological benefit remains to be validated. It emphasizes the critical role of multidisciplinary collaboration in diagnosis and treatment and adds new data to the limited literature on this rare disease.

P2, N=92, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting --> Recruiting

Inactivation of the pRB/p16 pathway is common, with 2/3 showing pRB loss. They present as advanced tumors and behave aggressively.

P2, N=54, Recruiting, Yale University | Initiation date: Mar 2026 --> Jun 2026

These tumors are highly aggressive with poor prognosis. The limited sample size shows a polarized trend in survival data.

P2, N=57, Active, not recruiting, University Health Network, Toronto | Trial completion date: Sep 2026 --> Sep 2027 | Trial primary completion date: May 2026 --> May 2027

P2, N=58, Active, not recruiting, University of Texas Southwestern Medical Center | Trial completion date: Jun 2027 --> Jun 2028 | Trial primary completion date: Jul 2026 --> Jul 2027

The presence of morules, which display nuclear β-catenin expression, places this lesion in the so-called BROCN family of tumors, which are believed to be hormonally driven. Further molecular studies are needed to explore the roots of their behavior.

This study establishes a fully automated CT-based deep learning pipeline for HER2 status prediction in unresectable GBC. Validation in larger, multi-institutional cohorts is warranted.

P2, N=107, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital

P1, N=24, Recruiting, Ruijin Hospital

P2, N=30, Not yet recruiting, HuiKai Li